With Novo Nordisk’s Wegovy weight-loss drug in short supply, the company’s owner agreed to buy contract manufacturer Catalent for $16.5 billion, including debt, to boost output.

Feb 5, 2024 | Uncategorized

With Novo Nordisk’s Wegovy weight-loss drug in short supply, the company’s owner agreed to buy contract manufacturer Catalent for $16.5 billion, including debt, to boost output.

Translate »
Contactar
1
Scan the code
Hola👋
¿Cómo podemos ayudarte?